Takeda Picks Next Big Thing In Immunotherapy: Gamma Delta T Cells

Takeda is aiming to get ahead in what it believes is an emerging area with big potential in immunotherapy: gamma delta T-cells. It has signed a deal with GammaDelta Therapeutics that gives it a purchase option on the UK-based, Abingworth-backed start-up. GammaDelta's CEO, former GSK executive Paolo Paoletti, and the head of Takeda's external innovation center, Dan Curran, spoke to Scrip.

Tools
Could gamma delta T cells provide an important new immunotherapy tool? • Source: Shutterstock

Checkpoint inhibitors and CAR-T cell therapy have become household words in pharma circles, but tissue-derived gamma delta T-cells are not widely talked about…yet. This relatively under-explored aspect of immune biology may be able to provide useful additional tools in the growing immunotherapy armamentarium, as a deal signed last week by Takeda Pharmaceutical Co. Ltd. highlights.

The Japanese firm has bought a stake in GammaDelta Therapeutics Ltd, a start-up spun out of UK academia only last...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By 

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip